LeMaitre Vascular (LMAT) Aktievy
LeMaitre Vascular, Inc. utvecklar, tillverkar och marknadsför medicintekniska produkter och implantat som används inom kärlkirurgi i Nord- och Sydamerika, Europa, Mellanöstern, Afrika och Asien/Stillahavsområdet. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 2/6 |
| Framtida tillväxt | 1/6 |
| Tidigare resultat | 5/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 4/6 |
LMAT Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
LeMaitre Vascular, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$81.45 |
| 52 veckors högsta | US$118.01 |
| 52 veckors lägsta | US$78.65 |
| Beta | 0.52 |
| 1 månads förändring | -20.01% |
| 3 månaders förändring | -24.54% |
| 1 års förändring | -11.74% |
| 3 års förändring | 45.92% |
| 5 års förändring | 47.53% |
| Förändring sedan börsintroduktionen | 1,213.71% |
Senaste nyheter och uppdateringar
Analysartikel • 15h
LeMaitre Vascular, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
One of the biggest stories of last week was how LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) shares plunged 21% in the week...
Ny berättelse • Aug 07
Global Expansion Risks And Supply Constraints Will Shape A Cautious Yet Constructive Outlook
Catalysts About LeMaitre Vascular LeMaitre Vascular develops, manufactures and sells devices and tissues for vascular and cardiac surgery worldwide. What are the underlying business or industry changes driving this perspective?Recent updates
Analysartikel • 15h
LeMaitre Vascular, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
One of the biggest stories of last week was how LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) shares plunged 21% in the week...Ny berättelse • Aug 07
Global Expansion Risks And Supply Constraints Will Shape A Cautious Yet Constructive Outlook
Catalysts About LeMaitre Vascular LeMaitre Vascular develops, manufactures and sells devices and tissues for vascular and cardiac surgery worldwide. What are the underlying business or industry changes driving this perspective?Analysartikel • Jun 20
LeMaitre Vascular (LMAT) Stock Could Be 20.9% Undervalued on Its International Growth Narrative
LeMaitre Vascular (LMAT) is back in focus after recent share price moves, with the stock last closing at US$93.95. Investors are weighing this level against the company’s fundamentals and recent return profile. See our latest analysis for LeMaitre Vascular. Recent momentum in LeMaitre Vascular has been mixed, with a 1-day share price return of 1.89% and a year to date share price return of 17.19%, while the 1-year total shareholder return stands at 15.94% and the 5-year total shareholder...
Uppdatering av berättelse • Jun 11
LMAT: Future Cash Returns May Support Raised 2026 Guidance And Premium P/E
Analysts have lifted their price target on LeMaitre Vascular by $25, citing updated assumptions around the discount rate, long term revenue growth, profit margins, and future P/E as key drivers of their revised view. Analyst Commentary Recent research updates on LeMaitre Vascular show a cluster of price target increases and a neutral initiation, providing a mix of both optimistic and cautious viewpoints on the stock.Uppdatering av berättelse • May 28
LMAT: Future Cash Returns May Support Raised Earnings Guidance And Premium P/E
LeMaitre Vascular's analyst price target has been updated to $118.75 from $111.22, as analysts factor in revised fair value assumptions, a slightly lower discount rate, modestly adjusted revenue growth expectations, and a higher projected P/E multiple supported by recent research updates from multiple firms. Analyst Commentary Recent research updates show a cluster of higher price targets for LeMaitre Vascular, alongside at least one more neutral stance, giving you a mix of optimistic and cautious views to weigh.Uppdatering av berättelse • Apr 27
LMAT: Future Cash Returns And Operating Leverage May Sustain Current Premium
Narrative Update on LeMaitre Vascular The updated analyst price target for LeMaitre Vascular moves to $117 from $108. This reflects analysts' focus on recent double digit organic growth, margin expansion, strong cash flow, and better than expected Q4 results with operating leverage.Uppdatering av berättelse • Apr 13
LMAT: Future Margin Discipline And Cash Returns May Support Current Premium
Narrative Update on LeMaitre Vascular The updated analyst price target for LeMaitre Vascular now reflects a modestly higher fair value estimate of about $111.22. This is supported by Street research that highlights continued double digit organic sales growth, material margin expansion, strong cash flow and operating leverage in the wake of better than expected Q4 results and guidance.Uppdatering av berättelse • Mar 29
LMAT: Future Cash Returns And Margin Discipline May Sustain Current Premium
Narrative Update Analysts have raised LeMaitre Vascular's price targets by $10 to $12, now in a $105 to $117 range. They cite double digit organic revenue growth, margin expansion, strong cash flow, better than expected Q4 results, and operating leverage.Uppdatering av berättelse • Mar 14
LMAT: Future Margin Execution And Capital Returns May Support Current Premium
Narrative Update on LeMaitre Vascular Our analyst fair value estimate for LeMaitre Vascular has been lifted from $109.22 to $111.00, reflecting updated price targets from $95 to $105 and from $108 to $117 as analysts point to double digit organic growth, margin expansion, and operating leverage following better than expected Q4 results and guidance. Analyst Commentary Recent price target increases to $105 and $117 signal that bullish analysts are incorporating stronger fundamentals into their models following the latest Q4 print and guidance.Uppdatering av berättelse • Feb 28
LMAT: Future Margin Gains And Capital Returns May Sustain Current Premium
Analysts have increased their implied fair value estimate for LeMaitre Vascular by about $4 to roughly $109, citing recent price target increases to $105 and $117 that they attribute to double-digit organic sales growth, margin expansion and operating leverage. Analyst Commentary Bullish Takeaways Bullish analysts point to double digit organic sales growth as a key support for their higher fair value views, seeing current revenue trends as consistent with a premium valuation versus slower growing peers.Seeking Alpha • Feb 27
LeMaitre Vascular: The Compounder Keeps Compounding
Summary LeMaitre Vascular delivered strong Q4 and FY 2025 results, with 16% YoY sales growth and broad-based margin expansion. Artegraft’s international rollout exceeded expectations, with 2025 sales doubling guidance and a projected $10M in 2026. This could drive earnings growth for years to come. LMAT maintains a robust $190M net cash position and recently increased its dividend by 25%. The board has also authorized a $100M share repurchase program. Operating leverage, pricing power, and international expansion are all key drivers in raising my price target to $116-$130 for year-end 2026. I reiterate my Buy rating. Read the full article on Seeking AlphaAnalysartikel • Feb 06
Here's Why LeMaitre Vascular (NASDAQ:LMAT) Has Caught The Eye Of Investors
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysartikel • Jan 03
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Shares May Have Run Too Fast Too Soon
With a price-to-earnings (or "P/E") ratio of 34.1x LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) may be sending very bearish...Analysartikel • Oct 26
Investors Met With Slowing Returns on Capital At LeMaitre Vascular (NASDAQ:LMAT)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'd want to...Analysartikel • Aug 30
Here's Why LeMaitre Vascular (NASDAQ:LMAT) Has Caught The Eye Of Investors
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysartikel • Aug 06
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Could Be 25% Above Their Intrinsic Value Estimate
Key Insights LeMaitre Vascular's estimated fair value is US$68.59 based on 2 Stage Free Cash Flow to Equity Current...Analysartikel • Jul 18
Is LeMaitre Vascular (NASDAQ:LMAT) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • Jun 18
Earnings Not Telling The Story For LeMaitre Vascular, Inc. (NASDAQ:LMAT)
LeMaitre Vascular, Inc.'s ( NASDAQ:LMAT ) price-to-earnings (or "P/E") ratio of 40.5x might make it look like a strong...Analysartikel • Apr 24
Should You Be Adding LeMaitre Vascular (NASDAQ:LMAT) To Your Watchlist Today?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysartikel • Apr 12
Does LeMaitre Vascular (NASDAQ:LMAT) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysartikel • Mar 31
LeMaitre Vascular (NASDAQ:LMAT) Will Want To Turn Around Its Return Trends
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...Analysartikel • Mar 11
LeMaitre Vascular's (NASDAQ:LMAT) Shareholders Will Receive A Bigger Dividend Than Last Year
LeMaitre Vascular, Inc.'s ( NASDAQ:LMAT ) dividend will be increasing from last year's payment of the same period to...Analysartikel • Mar 02
Earnings Update: Here's Why Analysts Just Lifted Their LeMaitre Vascular, Inc. (NASDAQ:LMAT) Price Target To US$105
Shareholders might have noticed that LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) filed its yearly result this time last...Analysartikel • Feb 04
When Should You Buy LeMaitre Vascular, Inc. (NASDAQ:LMAT)?
While LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) might not have the largest market cap around , it received a lot of...Analysartikel • Jan 22
We Ran A Stock Scan For Earnings Growth And LeMaitre Vascular (NASDAQ:LMAT) Passed With Ease
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Seeking Alpha • Jan 15
LeMaitre Vascular: Losing Steam
Summary LeMaitre Vascular, Inc. has seen a 65% stock rise over 12 months but trades at high valuations with decelerating growth projections. Q3 results showed strong performance with 46% profit growth and 15.7% revenue increase, driven by grafts, patches, and carotid shunts. The stock has dipped some 15% recently. Buy the dip? An analysis around LeMaitre Vascular follows in the paragraphs below. Read the full article on Seeking AlphaAnalysartikel • Jan 09
A Look At The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)
Key Insights LeMaitre Vascular's estimated fair value is US$96.24 based on 2 Stage Free Cash Flow to Equity Current...Analysartikel • Dec 22
LeMaitre Vascular (NASDAQ:LMAT) Has More To Do To Multiply In Value Going Forward
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analysartikel • Nov 24
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) 26% Price Boost Is Out Of Tune With Earnings
LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) shares have had a really impressive month, gaining 26% after a shaky period...Seeking Alpha • Nov 03
LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story
Summary LeMaitre continues to expand in the peripheral vascular disease market, with recent revenue gains driven by premium pricing and international growth. Its strong dividend growth of 14.3% this year and double-digit CAGR over the past five years are particularly appealing. With a high-margin, low-competition niche and accelerating geographic expansion, LeMaitre remains well-positioned for sustained growth. Read the full article on Seeking AlphaAnalysartikel • Nov 02
LeMaitre Vascular, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
As you might know, LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) just kicked off its latest quarterly results with some very...Analysartikel • Oct 08
Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Potentially Undervalued?
While LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) might not have the largest market cap around , it saw a double-digit...Analysartikel • Sep 17
Investors Met With Slowing Returns on Capital At LeMaitre Vascular (NASDAQ:LMAT)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...
Ny berättelse • Sep 11
Expanding Market Reach And Calculated Acquisitions Set To Fuel Robust Revenue And Earnings Growth
Expansion in North America and new regulatory approvals in Europe and Asia-Pacific indicate potential revenue growth from increased market share and customer reach.Analysartikel • Sep 04
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Price In Tune With Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 17x, you may...Analysartikel • Aug 22
If EPS Growth Is Important To You, LeMaitre Vascular (NASDAQ:LMAT) Presents An Opportunity
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Seeking Alpha • Jul 23
LeMaitre Vascular: A Small Cap With Best-In-Industry Growth
Summary I outline why LeMaitre Vascular is my top choice in the Health Care Equipment industry and one of the best small caps in the sector. LeMaitre has shown incredible revenue and EPS growth since its IPO and also offers a well-supported, fast-growing dividend. Despite a seemingly high valuation, further growth is expected. Read the full article on Seeking AlphaAnalysartikel • Jul 12
Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$85.0 Based On Its Intrinsic Value?
Key Insights LeMaitre Vascular's estimated fair value is US$70.02 based on 2 Stage Free Cash Flow to Equity Current...Analysartikel • Jun 18
Is There Now An Opportunity In LeMaitre Vascular, Inc. (NASDAQ:LMAT)?
LeMaitre Vascular, Inc. ( NASDAQ:LMAT ), might not be a large cap stock, but it led the NASDAQGM gainers with a...Analysartikel • Jun 05
Return Trends At LeMaitre Vascular (NASDAQ:LMAT) Aren't Appealing
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...Analysartikel • May 02
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Popularity With Investors Is Clear
With a price-to-earnings (or "P/E") ratio of 49.8x LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) may be sending very bearish...Analysartikel • Apr 04
Is Now The Time To Put LeMaitre Vascular (NASDAQ:LMAT) On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysartikel • Feb 29
Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)
Key Insights The projected fair value for LeMaitre Vascular is US$68.32 based on 2 Stage Free Cash Flow to Equity...Aktieägarnas avkastning
| LMAT | US Medical Equipment | US Marknad | |
|---|---|---|---|
| 7D | -19.6% | 1.6% | 3.5% |
| 1Y | -11.7% | -12.6% | 20.5% |
Avkastning vs industri: LMAT matchade US Medical Equipment branschen som gav -12.6 % under det senaste året.
Avkastning vs Marknaden: LMAT presterade sämre än US marknaden som gav 20.5 % under det senaste året.
Prisvolatilitet
| LMAT volatility | |
|---|---|
| LMAT Average Weekly Movement | 8.8% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: LMAT har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: LMAT s veckovolatilitet ( 9% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1983 | 651 | George LeMaitre | www.lemaitre.com |
LeMaitre Vascular, Inc. utvecklar, tillverkar och marknadsför medicintekniska produkter och implantat som används inom kärlkirurgi i Nord- och Sydamerika, Europa, Mellanöstern, Afrika och Asien/Stillahavsområdet. Företaget erbjuder allografts, som är kryokonserverade mänskliga vävnadstransplantat som används vid kärlrekonstruktion samt reparation och rekonstruktion av hjärtat, embolektomikatetrar för att avlägsna blodproppar från artärer, trombektomikatetrar för att avlägsna tromber i det venösa systemet, ocklusionskatetrar som tillfälligt stänger av blodflödet och perfusionskatetrar för att tillföra blod och andra vätskor till kärlsystemet samt tjänster för kryokonservering av vävnad från mänskliga lik. Företaget tillhandahåller en serie biologiska produkter som omfattar det biologiska transplantatet artegraft, en halspulsåder från nötkreatur som används för dialysaccess, XenoSure biologiska plåster som används för att stänga kärl efter kirurgiska ingrepp, VascuCel och CardioCel biologiska plåster som används för kärlreparation, reparation och rekonstruktion av hjärtat samt neonatala reparationer; carotis-shuntar som tillfälligt shuntar blodet till hjärnan, biosyntetiska kärlgrafts för bypass i nedre extremiteterna och dialysaccess, flebektomisystem för resektion och ablation av åderbråck, LifeSpan kärlgrafts, som är expanderade polytetrafluoretylengrafts, samt kärlgrafts som används för bypass eller ersättning av sjuka artärer.
LeMaitre Vascular, Inc. Sammanfattning av grunderna
| LMAT grundläggande statistik | |
|---|---|
| Börsvärde | US$1.86b |
| Vinst(TTM) | US$65.67m |
| Intäkter(TTM) | US$262.43m |
28.4x
P/E-förhållande7.1x
P/S-förhållandeÄr LMAT övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| LMAT resultaträkning (TTM) | |
|---|---|
| Intäkter | US$262.43m |
| Kostnad för intäkter | US$73.83m |
| Bruttovinst | US$188.61m |
| Övriga kostnader | US$122.93m |
| Intäkter | US$65.67m |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 2.87 |
| Bruttomarginal | 71.87% |
| Nettovinstmarginal | 25.02% |
| Skuld/egenkapitalförhållande | 40.2% |
Hur har LMAT utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
1.2%
Aktuell utdelningsavkastning31%
UtbetalningskvotGer LMAT en tillförlitlig utdelning?
Se LMAT utdelningshistorik och jämförelsetal| LeMaitre Vascular datum för utdelning | |
|---|---|
| Ex utdelningsdag | Aug 20 2026 |
| Utbetalningsdag för utdelning | Sep 03 2026 |
| Dagar till Ex-utdelning | 12 days |
| Dagar till utdelningsdag | 26 days |
Ger LMAT en tillförlitlig utdelning?
Se LMAT utdelningshistorik och jämförelsetalFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/07 23:42 |
| Aktiekurs vid dagens slut | 2026/08/07 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
LeMaitre Vascular, Inc. bevakas av 19 analytiker. 9 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Jan Wald | Benchmark Company |
| Raymond Myers | Benchmark Company |